Xenon Pharmaceuticals Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2018 Annual Meeting of Shareholders held by Xenon Pharmaceuticals Inc. on June 4, 2018. The filing details the voting results for three proposals submitted to security holders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
Shareholders representing approximately 56.6% of total shares entitled to vote (8,457,334 common shares) participated in the meeting. The following proposals were approved:
- Proposal One (Election of Directors): All nine nominees were elected. Notable voting patterns included significant "Withhold" votes for Frank Holler (1,282,334 votes) compared to other nominees who received fewer than 152,000 withhold votes. Broker non-votes totaled 2,623,879 for all director nominees.
- Proposal Two (Appointment of Auditor): The appointment of KPMG LLP as the independent registered public accounting firm was approved with 8,374,954 votes "For" and 82,380 "Withhold".
- Proposal Three (Auditor Remuneration): The authorization for the Audit Committee to set auditor remuneration was approved with 8,288,875 votes "For" and 168,459 "Against".
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the specific reasons for the elevated "Withhold" votes cast against director nominee Frank Holler.
- Confirm the total number of outstanding shares to contextualize the 56.6% participation rate.
- Review the definitive proxy statement filed on April 27, 2018, for detailed biographies of the elected directors and the rationale for the auditor appointment.